These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 18333911

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.
    Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM.
    J Clin Invest; 2000 Jul; 106(1):107-16. PubMed ID: 10880054
    [Abstract] [Full Text] [Related]

  • 25. In vitro and in vivo effects of desmopressin on platelet function.
    Balduini CL, Noris P, Belletti S, Spedini P, Gamba G.
    Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. hEPCR.hTBM.hCD47.hHO-1 with donor clodronate and DDAVP treatment improves perfusion and function of GalTKO.hCD46 porcine livers perfused with human blood.
    Cimeno A, Kuravi K, Sorrells L, Dandro A, Sendil S, Burdorf L, Parsell DM, Eyestone W, Phelps C, Ayares D, Azimzadeh AM, Pierson RN, Barth RN, LaMattina JC.
    Xenotransplantation; 2022 Mar; 29(2):e12731. PubMed ID: 35166407
    [Abstract] [Full Text] [Related]

  • 29. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells.
    Hashemi S, Palmer DS, Aye MT, Ganz PR.
    J Cell Physiol; 1993 Mar; 154(3):496-505. PubMed ID: 8436598
    [Abstract] [Full Text] [Related]

  • 30. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS, Derkx FH, Boomsma F, Brommer EJ, Schalekamp MA.
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB.
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [Abstract] [Full Text] [Related]

  • 38. Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction.
    Gaca JG, Appel JZ, Lukes JG, Gonzalez-Stawinski GV, Lesher A, Palestrant D, Logan JS, Love SD, Holzknecht ZE, Platt JL, Parker W, Davis RD.
    Transplantation; 2006 Jun 27; 81(12):1686-94. PubMed ID: 16794535
    [Abstract] [Full Text] [Related]

  • 39. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
    Kinter LB, McConnell I, Goodwin BT, Campbell S, Huffman WF, Arthus MF, Lonergan M, Bichet DG.
    J Pharmacol Exp Ther; 1992 May 27; 261(2):462-9. PubMed ID: 1578361
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.